Prime Editing for Wilson's Disease

(PM577a Trial)

This trial tests a new treatment called PM577a, a prime editing therapy, for individuals with Wilson disease, a genetic condition that prevents the body from eliminating excess copper. The trial aims to determine if a single IV infusion of PM577a is safe and can correct a common gene mutation responsible for the disease, potentially improving copper balance in the body. This treatment is being tested in humans for the first time, with a focus on safety and initial effectiveness. Individuals with Wilson disease who have the specific gene mutation (p.H1069Q) and have maintained stability on their current treatment for at least six months may be suitable candidates for the trial. As a Phase 1 trial, this research seeks to understand how the treatment functions in humans, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial requires that you have been stable on your current Wilson disease medications for at least 6 months before joining. It doesn't specify if you need to stop them during the trial, so you should discuss this with the study team.

Research shows that PM577a is a new treatment being tested for Wilson disease. As this is the first trial involving humans, no previous human data on its safety exists. The "Phase 1/Phase 2" trial primarily aims to assess the treatment's safety and tolerability. Early trials like this typically begin with small doses to monitor side effects closely.

Most treatments for Wilson's disease focus on reducing copper accumulation using chelating agents like penicillamine or zinc therapy. However, PM577a works differently by using Prime Editing, a groundbreaking gene-editing technique, to directly target and correct the genetic mutations causing Wilson's disease. This treatment is administered as a single dose intravenous infusion, which could potentially offer a more efficient and long-lasting solution compared to current daily therapies. Researchers are excited about PM577a because it promises a targeted, one-time intervention that addresses the root cause of the disorder rather than just managing symptoms.

Research has shown that PM577a, the treatment under study in this trial, is designed to help people with Wilson disease by addressing a common issue in the ATP7B gene. This issue prevents the body from eliminating excess copper, leading to health problems. PM577a aims to correct this, enabling the body to manage copper levels more effectively. Although new for humans, this treatment uses Prime Editing technology, which has shown promise in accurately fixing genetic problems. The therapy could potentially improve copper management and reduce symptoms in people with Wilson disease. Initial results on its effectiveness are expected in 2027.²⁶⁷⁸⁹